DK3269736T3 - Konformationsspecifikke antistoffer mod oligomerer af amyloid beta - Google Patents
Konformationsspecifikke antistoffer mod oligomerer af amyloid beta Download PDFInfo
- Publication number
- DK3269736T3 DK3269736T3 DK17185247.8T DK17185247T DK3269736T3 DK 3269736 T3 DK3269736 T3 DK 3269736T3 DK 17185247 T DK17185247 T DK 17185247T DK 3269736 T3 DK3269736 T3 DK 3269736T3
- Authority
- DK
- Denmark
- Prior art keywords
- oigomers
- conformity
- antibodies against
- specific antibodies
- amyloid beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12167565 | 2012-05-10 | ||
EP13724769.8A EP2847217B1 (en) | 2012-05-10 | 2013-05-08 | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3269736T3 true DK3269736T3 (da) | 2020-01-13 |
Family
ID=48485135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17185247.8T DK3269736T3 (da) | 2012-05-10 | 2013-05-08 | Konformationsspecifikke antistoffer mod oligomerer af amyloid beta |
Country Status (5)
Country | Link |
---|---|
US (1) | US9617332B2 (da) |
EP (2) | EP2847217B1 (da) |
DK (1) | DK3269736T3 (da) |
HK (2) | HK1207869A1 (da) |
WO (1) | WO2013167681A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107531781B (zh) * | 2015-01-29 | 2021-12-07 | 抗菌技术,生物技术研究与发展股份有限公司 | 用于阿尔茨海默病和相关紊乱的抗体分子和肽递送系统 |
GB2541003A (en) * | 2015-08-05 | 2017-02-08 | Kran Life Sciences Llp | Neurodegenerative disorders |
US10870709B2 (en) | 2016-07-22 | 2020-12-22 | New York University | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides |
KR20210080400A (ko) * | 2018-10-04 | 2021-06-30 | 게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진 | 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체 |
CA3167073A1 (en) | 2020-03-10 | 2021-09-16 | Preeti BAKRANIA | Cyclic peptides |
CN112816533A (zh) * | 2020-12-31 | 2021-05-18 | 商丘师范学院 | 一种铜纳米簇作为电化学信号探针的β-淀粉样蛋白寡聚体传感器 |
CN117586388A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 改进的β淀粉样蛋白寡聚体特异性结合抗体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPWO2005105998A1 (ja) | 2004-04-27 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
AU2008312802A1 (en) | 2007-10-19 | 2009-04-23 | Immunas Pharma, Inc. | Antibody capable of specifically binding to abeta oligomer, and use thereof |
EP2205633A1 (en) | 2007-10-29 | 2010-07-14 | Innogenetics N.V. | New antibodies specific of the -amyloid peptides and their uses as diagnostic agents or drugs |
NZ583632A (en) * | 2007-11-16 | 2012-05-25 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
CA2714413C (en) | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Antibody capable of binding specifically to ab-oligomer, and use thereof |
US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
-
2013
- 2013-05-08 EP EP13724769.8A patent/EP2847217B1/en active Active
- 2013-05-08 DK DK17185247.8T patent/DK3269736T3/da active
- 2013-05-08 EP EP17185247.8A patent/EP3269736B1/en active Active
- 2013-05-08 US US14/399,639 patent/US9617332B2/en active Active
- 2013-05-08 WO PCT/EP2013/059632 patent/WO2013167681A1/en active Application Filing
-
2015
- 2015-08-31 HK HK15108504.5A patent/HK1207869A1/xx unknown
-
2018
- 2018-07-03 HK HK18108559.6A patent/HK1249116A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3269736B1 (en) | 2019-11-27 |
US20150118239A1 (en) | 2015-04-30 |
HK1249116A1 (zh) | 2018-10-26 |
HK1207869A1 (en) | 2016-02-12 |
EP2847217A1 (en) | 2015-03-18 |
EP2847217B1 (en) | 2017-10-11 |
WO2013167681A8 (en) | 2014-03-06 |
EP3269736A1 (en) | 2018-01-17 |
WO2013167681A1 (en) | 2013-11-14 |
US9617332B2 (en) | 2017-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7020871A2 (es) | Anticuerpos anti-il-36r | |
BR112014024769A2 (pt) | anticorpo humanizado tau | |
DK2845905T3 (da) | Fremstilling af oligosaccharider | |
DK2934584T3 (da) | Anti-gdf15-antistoffer | |
DK2850101T3 (da) | Anti-FcRn-antistoffer | |
DK2961388T3 (da) | Kombinationer af lægemidler | |
DK2771364T3 (da) | Fremstilling af heterodimere proteiner | |
DK3252076T3 (da) | Diagnostisk anvendelse af antistoffer mod ror-1-protein | |
DK3052004T3 (da) | Diagnose af synsstabilitetsdysfunktion | |
CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
DK3454346T3 (da) | Anordning til cylotronfremstilling af technetium-99m | |
DK2768524T3 (da) | PD-L1-baseret immunterapi | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK2679008T3 (da) | Multi-metrik filtrering | |
DK2970954T3 (da) | Modifikation af polypeptider | |
DK3017039T3 (da) | Funktionalisering af endogene bakterier | |
DK2802865T3 (da) | Overvågning af motorkomponenter | |
CR20140127A (es) | Anticuerpo anti-abtcr | |
UY4115Q (es) | Reloj | |
DK3115448T3 (da) | Fremstilling af en pulverformig eddike | |
DK3219801T3 (da) | Konstruktion | |
DK3038643T3 (da) | Antistoffer mod csf-1r | |
DK2969098T3 (da) | Fremgangsmåder til oprensning af antistoffer | |
DK3269736T3 (da) | Konformationsspecifikke antistoffer mod oligomerer af amyloid beta | |
DK2931313T3 (da) | Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer |